Vimarsana
Biggest News Aggregation in the World

Page 3 - Thomasj Smith News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Thomasj Smith. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Thomasj Smith Today - Breaking & Trending Today

The 2022 Law Power 100 - Vimarsana News

The 2022 Law Power 100

The legal eagles influencing Pennsylvania politics from local to national levels.

Panel discusses infrastructure, safety at Marshall symposium - Vimarsana News

Panel discusses infrastructure, safety at Marshall symposium

HUNTINGTON — A shared roadway is the way of the future to reduce traffic fatalities among pedestrians, bicyclists and people in a vehicle, experts said during a symposium at Marshall

Panel to discuss infrastructure, safety at Marshall University - Vimarsana News

Panel to discuss infrastructure, safety at Marshall University

HUNTINGTON — Marshall University’s Society of Yeager Scholars’ spring symposium Thursday will feature a discussion on campus infrastructure and safety.

When patient expectations battle with reality - Vimarsana News

When patient expectations battle with reality

TAM is fast approaching, which means one thing (at least this year). I need to get my Plexiglass blinky posterior in gear in order to have my talks together in time. I spent part of yesterday doing that, but, unfortunately, I have to work today in order to help to make up for the clinic I'll be missing next week; so you'll forgive me if this post might look familiar to a subset of you who know where you might have seen some of this discussion before elsewhere. Those of you who haven't, you're in for some good blogging, if I do say so myself.

FDA restricts use of Intercept drug due to liver injury risk - Vimarsana News

FDA restricts use of Intercept drug due to liver injury risk

Dive Brief: The Food and Drug Administration on Wednesday restricted the use of Intercept Pharmaceuticals' liver disease drug Ocaliva after an investigation linked it to severe injuries including liver failure in certain patients. In most cases, the benefits of Ocaliva outweigh the risks for patients with primary biliary cholangitis, the FDA said. But the agency announced Wednesday that doctors should not prescribe the medicine for patients with advanced cirrhosis, or permanent scarring. The new contraindication follows a safety warning added in 2018 to caution physicians about overdosing pat...